Compensation for COVID-19 Vaccine Injuries

Updated March 31, 2023
Compensation for COVID-19 Vaccine Injuries

More than 260 million Americans, and billions of people worldwide, have received one or more doses of a vaccine to protect against Coronavirus Disease 2019 (COVID-19). Most common side effects of COVID-19 vaccines are mild and generally resolve in a few days. In rare instances, COVID-19 vaccines can cause serious adverse events.

Individuals who believe they are injured by COVID-19 vaccines may seek compensation for those injuries and associated harms or costs. Absent an applicable federal law, individuals allegedly injured by a vaccine might seek redress by filing a state tort law claim against the vaccine manufacturer. However, federal law has two distinct compensation regimes that limit legal liability for vaccine manufacturers and provide potential compensation—without requiring a showing of fault—for individuals harmed by adverse reactions to vaccines.

For injuries and deaths associated with most vaccines recommended by the Centers for Disease Control and Prevention (CDC) for routine administration in the United States, the National Vaccine Injury Compensation Program (VICP) may provide compensation. During public health emergencies declared under the Public Readiness and Emergency Preparedness Act (PREP Act), the Countermeasures Injury Compensation Program (CICP) may provide compensation for injuries and deaths resulting from the administration of “covered countermeasures,” which may include vaccines.

The VICP and CICP regimes are similar in some ways, but the programs serve distinct purposes. Compensation through CICP is generally less comprehensive than through VICP. CICP is a regulatory process administered by the Health Resources and Services Administration (HRSA), a division of the U.S. Department of Health and Human Services (HHS). CICP compensation is available only for death or serious injuries resulting from a covered countermeasure. A claimant must generally file a request form and associated documentation with HRSA within one year of the date that the covered countermeasure was administered. For injuries not listed by the Secretary of HHS on a Countermeasure Injury Table, the claimant must demonstrate that the injury was a direct result of the countermeasure’s administration based on compelling medical and scientific evidence. HRSA makes decisions regarding eligibility and compensation; judicial review is not available. CICP compensation is limited to reasonable medical expenses, loss of employment income, and a death benefit when the claimant’s death is a direct result of the administration of a covered countermeasure.

Under the Secretary of HHS’s current PREP Act Declaration for COVID-19, FDA-authorized or -approved COVID-19 vaccines are covered countermeasures. While a PREP Act declaration is in effect, CICP is the sole remedy available for injuries related to covered countermeasures, so CICP—and not VICP—will apply to injuries resulting from COVID-19 vaccinations while the Declaration remains in effect. Due to COVID-19, the number of CICP claims has increased dramatically. As of February 1, 2023, CICP has received 11,252 claims alleging injury or death relating to COVID-19 countermeasures. Of those, 8,067 claims (71.7%) relate to COVID-19 vaccines. HRSA has not yet compensated any CICP claims relating to COVID-19 countermeasures.

When coverage under the PREP Act Declaration for COVID-19 ends, COVID-19 vaccine injuries could be compensated through VICP, contingent on additional regulatory and statutory changes. To be included in the VICP, (1) the vaccine must be recommended by the CDC for routine administration to children or pregnant women; (2) the vaccine must be made subject by act of Congress to the excise tax that funds VICP; and (3) the Secretary of HHS must add the vaccine to the Vaccine Injury Table, which lists injuries and conditions associated with vaccines covered by VICP. Should all of these changes occur, COVID-19 vaccines would be covered by VICP.

To receive compensation through VICP for a vaccine-related injury or death, the injured person or their estate must file a petition with the U.S. Court of Federal Claims, generally within three years of the onset of the first symptom or significant aggravation of the injury, or within two years of death or four years of the first symptom resulting in death. To receive compensation, petitioners must show either that they experienced an injury listed in the Vaccine Injury Table within the time frame specified in the Table, or prove that the vaccine was the “but-for” cause of their injury. Special masters determine eligibility and compensation; their decisions may be appealed to the U.S. Court of Federal Claims and the U.S. Court of Appeals for the Federal Circuit. Successful petitioners may receive medical expenses, lost income, a set death benefit, and reasonable attorneys’ fees and costs. Petitioners who are dissatisfied with the compensation they receive, or whose claims are delayed, may opt to pursue civil actions in court, subject to certain limitations on vaccine manufacturer liability.
Contents

The Countermeasures Injury Compensation Program (CICP) .......................................................... 3
  Covered Vaccines and Injuries ........................................................................................................ 4
  Procedure for Obtaining Compensation ...................................................................................... 4
  Available Compensation ................................................................................................................. 5
  Status of Pending CICP Claims for COVID-19 Countermeasures ................................................. 6
The National Vaccine Injury Compensation Program (VICP) ................................................................. 7
  Covered Vaccines and Injuries ........................................................................................................ 8
  Procedure for Obtaining Compensation ...................................................................................... 8
  Available Compensation ................................................................................................................. 11
Possible Transition of COVID-19 Vaccines from Coverage Under CICP to VICP ......................... 11
Considerations for Congress ................................................................................................................ 13

Appendixes

Appendix. Comparison of Vaccine-Injury Programs: CICP vs. VICP .............................................. 16

Contacts

Author Information ................................................................................................................................. 17
More than 260 million Americans have received one or more doses of a Coronavirus Disease 2019 (COVID-19) vaccine, along with billions of people worldwide. The Food and Drug Administration’s (FDA’s) emergency use authorizations for the Pfizer-BioNTech, Moderna, Johnson & Johnson, and Novavax COVID-19 vaccines were based on months-long clinical trials (including safety monitoring) of each vaccine, involving tens of thousands of participants. These trials did not identify any safety concerns that would preclude emergency use authorization. Subsequently, the Pfizer-BioNTech COVID-19 vaccine (later known as Comirnaty) received full FDA approval as a two-dose primary series for individuals 12 years of age and older, and the Moderna COVID-19 vaccine (later known as Spikevax) received full FDA approval as two-dose primary series for individuals 18 years of age and older.

Following authorization, the COVID-19 vaccines have been subject to safety monitoring requirements by FDA and the Centers for Disease Control and Prevention (CDC) to track the incidence of side effects and detect long-term, rare, or unexpected adverse health events. The most common side effects of COVID-19 vaccines are mild—such as local pain around the injection site, fatigue, or fever—and usually resolve within a few days. As with most vaccines, however, a small percentage of inoculated individuals experience serious adverse reactions to a COVID-19 vaccine. For example, approximately five people per million receiving mRNA COVID-19 vaccines experience anaphylaxis, a severe allergic reaction, following vaccination. (In part for this reason, the CDC recommends that all individuals be monitored for at least 15 minutes following their vaccinations, and that all vaccination sites have epinephrine available for

4 Pfizer EUA, supra note 3, at 2; Moderna EUA, supra note 3, at 2; J&J EUA, supra note 3, at 2.
10 Id. (“Anaphylaxis after COVID-19 vaccination is rare and has occurred at a rate of approximately 5 cases per one million vaccine doses administered.”); accord Tom T. Shimabukuro, Matthew Cole & John R. Su, Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US: December 14, 2020–January 18, 2021, 325 JAMA 1101–02 (Feb. 12, 2021), https://jamanetwork.com/journals/jama/fullarticle/2776557 (reporting rates of 2.5 to 4.7 cases of anaphylaxis per million doses administered).
treatment of anaphylaxis.\(^{11}\) Other serious adverse events reported following vaccination, such as myocarditis and Guillain-Barré Syndrome (GBS), are similarly rare but are associated with some COVID-19 vaccines in some populations.\(^{12}\) For example, because of the rare risk of thrombosis with thrombocytopenia syndrome and GBS associated with Johnson & Johnson COVID-19 vaccine, CDC recommends use of mRNA COVID-19 vaccines in preference to the Johnson & Johnson vaccines for most patients.\(^{13}\)

Federal law has two distinct compensation regimes for individuals harmed by adverse reactions to vaccines. In general, the National Vaccine Injury Compensation Program (VICP) may provide compensation for injuries or deaths associated with most vaccines routinely administered in the United States (such as pediatric and seasonal influenza vaccines).\(^{14}\) During certain public health emergencies, the Countermeasures Injury Compensation Program (CICP) may provide compensation for injuries and deaths resulting from the administration of “covered countermeasures,” which may include vaccines, under the Public Readiness and Emergency Preparedness Act (PREP Act).\(^{15}\)

Under the Secretary of Health and Human Services’ (HHS’s) PREP Act Declaration for COVID-19 (and its amendments), COVID-19 vaccines are considered covered countermeasures within the PREP Act’s scope.\(^{16}\) As a result, CICP—and not VICP—currently applies to injuries resulting from COVID-19 vaccinations while the public health emergency persists and the Declaration


\(^{13}\) See Sara E. Oliver et al., Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021, 71 MMWR 90, 94 (Jan. 21, 2022), https://www.cdc.gov/mmwr/volumes/71/wr/mm7103a4.htm.


remains in force.\textsuperscript{17} Compensation through CICP is generally somewhat more limited than through VICP.\textsuperscript{18}

This report reviews and compares the compensation regimes available for vaccine-related injuries under CICP and VICP, and describes the procedures for injured individuals to obtain compensation under each program. The report concludes with an Appendix that compares the two regimes.

**The Countermeasures Injury Compensation Program (CICP)**

To encourage expeditious development and deployment of medical countermeasures during a public health emergency, the PREP Act authorizes the Secretary of HHS (the Secretary) to limit legal liability for losses resulting from the administration of medical countermeasures such as diagnostics, treatments, and vaccines.\textsuperscript{19} In a declaration effective February 4, 2020 (the PREP Act Declaration), the Secretary invoked the PREP Act and declared the spread of COVID-19 to be a public health emergency warranting liability protections for covered countermeasures (e.g., drugs, biologics, and medical devices used to diagnose, treat, or prevent COVID-19).\textsuperscript{20} Pursuant to the PREP Act Declaration and its subsequent amendments,\textsuperscript{21} manufacturers, distributors, and health care providers are generally immune from legal liability (i.e., they cannot be sued for money damages in court) for losses related to the administration or use of covered countermeasures against COVID-19.\textsuperscript{22}

In addition to providing immunity from liability, the PREP Act established CICP, a compensation program for individuals seriously injured or killed as a direct result of the administration or use of a covered countermeasure.\textsuperscript{23} CICP is a regulatory process administered by the Health Resources and Services Administration (HRSA).\textsuperscript{24} HRSA regulations govern CICP’s procedures and eligibility determinations.\textsuperscript{25}

\textsuperscript{17} Frequently Asked Questions, HRSA, https://www.hrsa.gov/cicp/faq (last visited Jan. 25, 2023) (“COVID-19 vaccines are covered countermeasures under the Countermeasures Injury Compensation Program (CICP), not the National Vaccine Injury Compensation Program (VICP).”).

\textsuperscript{18} See Comparison of Countermeasures Injury Compensation Program (CICP) to the National Vaccine Injury Compensation Program (VICP), HRSA, https://www.hrsa.gov/cicp/cicp-vicp (last updated Apr. 2021); see also infra “Appendix. Comparison of Vaccine-Injury Programs: CICP vs. VICP.”

\textsuperscript{19} 42 U.S.C. § 247d-6(a)–(b).


\textsuperscript{25} See 42 C.F.R. pt. 110.
Covered Vaccines and Injuries

Under the PREP Act and the amended PREP Act Declaration, covered countermeasures for COVID-19 may include drugs, biological products, and medical devices that the FDA approves, licenses, or authorizes for emergency use “to diagnose, mitigate, prevent, treat, or cure” COVID-19, or used “to limit the harm that COVID-19 . . . might otherwise cause.” For example, personal protective equipment (PPE) (e.g., respirators), ventilators, therapeutic drugs (e.g., Paxlovid), and monoclonal antibody treatments approved or authorized by FDA to treat or prevent COVID-19 are covered countermeasures under the PREP Act. Notably, FDA-authorized or -approved COVID-19 vaccines—such as those produced by Pfizer, Moderna, Johnson & Johnson, and Novavax—are covered countermeasures under the PREP Act Declaration.

Under the PREP Act, CICP remedies “shall be exclusive of any other civil action or proceeding” for injuries directly caused by administering covered countermeasures, with limited exceptions. Thus, while the current PREP Act Declaration and public health emergency remain in effect, CICP is the exclusive remedy for claims within the PREP Act’s scope, including injuries resulting from COVID-19 vaccinations. As discussed below in “Possible Transition of COVID-19 Vaccines from Coverage Under CICP to VICP,” COVID-19-vaccine-related injuries may eventually be compensable through the VICP after the PREP Act Declaration no longer applies, contingent on certain statutory and regulatory changes.

CICP compensation is limited to eligible individuals, such as persons injured by countermeasures or their survivors. CICP provides compensation only for death or “serious physical injuries”—that is, injuries that warrant hospitalization or lead to a significant loss of function or disability. Individuals who experience only minor, short-term side effects from a COVID-19 vaccine—such as mild soreness, headache, or fatigue—would not be eligible for CICP compensation.

Procedure for Obtaining Compensation

To apply for CICP compensation, a claimant generally must file a request for benefits within one year of the date the countermeasure was administered. (If the Secretary publishes a new Countermeasure Injury Table, a newly eligible claimant may file within one year after the new

---

30 See 42 C.F.R. § 110.10.
31 See id. § 110.3(2); 42 U.S.C. § 247d-6e(e)(3).
33 42 C.F.R. § 110.42(a).
Compensation Programs for COVID-19 Vaccine Injuries

Table is established. In addition to the request form, claimants may need to submit medical records and other evidence to establish eligibility. If determined to be eligible, claimants may submit additional documentation to demonstrate the compensation amount. Eligibility and compensation determinations are made by HRSA (exercising power delegated by the Secretary). Claimants may seek reconsideration of an adverse eligibility decision by HRSA, but the ultimate decisionmaking authority lies with the Secretary. The PREP Act precludes judicial review of the Secretary’s eligibility and compensation decisions.

CICP claimants can prove eligibility for compensation in one of two ways. The first applies only to injuries listed on a Countermeasure Injury Table, which the Secretary must establish by regulation when compelling medical and scientific evidence shows that administration or use of a covered countermeasure directly causes particular injuries. (The Table established for the H1N1 pandemic influenza vaccine is one example; no such table has yet been promulgated for any COVID-19 countermeasure, including vaccines.) For injuries listed on a Countermeasure Injury Table, if the claimant can show that the countermeasure recipient’s injury is listed on the Table and was sustained within the relevant time interval (and meets any other requirements set forth in the Table), CICP will presume the injury was a direct result of the covered countermeasure. For injuries not on a Countermeasure Injury Table (or outside its scope), the claimant must prove the non-Table injury was the “direct result” of the countermeasure’s administration based on “compelling, reliable, valid, medical and scientific evidence” beyond mere temporal association.

Available Compensation

Compensation under CICP is limited to (1) reasonable medical expenses (e.g., unreimbursed hospitalization costs); (2) loss of employment income (e.g., income lost from inability to work due to disability); and (3) a set death benefit where the death is a direct result of the administration or use of a covered countermeasure. Attorneys’ fees and pain-and-suffering damages are not available under CICP. CICP awards are also subject to various annual and

---

34 Id. § 110.42(f).
35 See id. § 110.50–110.53; see also Criteria to Demonstrate that a Covered Injury Occurred, HRSA, https://www.hrsa.gov/cicp/injury-occurred (last updated Dec. 2022).
37 See 42 C.F.R. § 110.72–110.74.
38 See id. §§ 110.90 (process to request reconsideration of eligibility determinations), 110.91 (“[T]he Secretary may, at any time, on her own motion or on application, review any determination made under this part [and] may affirm, vacate, or modify the determination in any manner the Secretary deems appropriate.”).
40 See 42 C.F.R. § 110.20(b)–(c).
42 42 C.F.R. § 110.100.
43 See id. § 110.20(b).
44 See id. § 110.20(c).
45 Id. § 110.2(a).
46 See Comparison of Countermeasures Injury Compensation Program (CICP) to the National Vaccine Injury Compensation Program (VICP), HRSA, https://www.hrsa.gov/cicp/cicp-vicp (last updated Apr. 2021) (“Attorneys’ fees and costs are not paid by [CICP].”); Nicholas M. Pace, Lloyd Dixon & Bethany Saunders-Medina, The
lifetime limits. For example, annual lost employment income awards are capped at $50,000 per
year, the standard maximum death benefit is the same as that under the Public Safety Officers’
Benefits program (currently $422,035).48

Given the limited number and scope of past PREP Act declarations, CICP has been used
relatively infrequently since the PREP Act’s 2005 enactment prior to the COVID-19 pandemic.49
The majority of the non-COVID-19 CICP claims have been related to alleged injuries from the
H1N1 pandemic influenza vaccine.50 According to HRSA, for FY2010 through FY2023, CICP
received 513 claims unrelated to COVID-19.51 Of these, 40 claims (7.8%) were determined to be
eligible for compensation and 30 claims (5.8%) have been paid out by CICP, amounting to over
$6 million in awards.52 (Ten of the claims determined to be eligible for compensation had no
eligible reported medical expenses or lost employment income.) All but one of the 30 claims
compensated by CICP to date relate to injuries from the H1N1 influenza vaccine.53

Status of Pending CICP Claims for COVID-19 Countermeasures

Due to the COVID-19 pandemic, the number of CICP claims HRSA has received has increased
dramatically. As of February 1, 2023, CICP has received 11,252 claims alleging injury or death
relating to COVID-19 countermeasures, of which 8,067 claims (71.7%) relate to COVID-19
vaccines.54 HRSA has not yet compensated any CICP claims relating to COVID-19
countermeasures. Of the 630 COVID-19 claims in which HRSA has reached a decision on
eligibility, it has denied 609 claims (96.7%) on various grounds, while determining that 21 claims
(3.3%) are eligible for compensation, pending a review of the eligible expenses.55 The remaining
COVID-19 countermeasure claims (approximately 94.4%) are in review or pending review.56

Several COVID-19 emergency appropriations allow the Secretary to transfer funds to the
Covered Countermeasure Process Fund.57 HRSA can use such funds, in addition to prior-year
fund balances, for CICP compensation awards.

Compensation Programs for COVID-19 Vaccine Injuries

Compensation System for Potential Side Effects Is an Important Part of a COVID-19 Vaccine Campaign,
https://www.rand.org/blog/2020/12/the-compensation-system-for-potential-side-effects.html (“The CICP does not provide any compensation for pain, suffering, emotional distress, or similar damages . . . .”).

47 42 C.F.R. § 110.81(c)(2).
48 Id. § 110.82(b)(1); Benefits by Year: Public Safety Officers‘ Benefits Program, U.S. Dep’t of Justice Bur. of Just.
49 See Pace et al., supra note 46 (“The NVICP has handled more than 20,000 vaccine injury claims since its inception,
while the CICP, as far as can be determined, has processed about 500 since the law that created the program was
enacted in 2005 [and prior to COVID-19].”).
50 See Bernard Condon & Matt Sedensky, How U.S. Government Will Handle COVID-19 Vaccine Injury Claims Is
(“Prior to COVID-19, the vast majority of the claims under [CICP] have stemmed from the H1N1 swine flu vaccine a
decade ago.”).
51 See Countermeasures Injury Compensation Program (CICP) Data, HRSA, https://www.hrsa.gov/cicp/cicp-data (last
updated Mar. 1, 2023) (listing 11,765 total claims, of which 11,252 relate to COVID-19 countermeasures).
52 See id. at tbls. 4 & 5.
53 See id. at tbl. 4. The other claim was for an injury associated with the smallpox vaccine.
54 See id. at tbl. 1.
55 See id. (listing CICP data for COVID-19 claims as of Mar. 1, 2023).
56 See id.
The National Vaccine Injury Compensation Program (VICP)

After the Secretary terminates the PREP Act Declaration for the COVID-19 pandemic, any injuries or death related to COVID-19 vaccine administration would be addressed in court under tort law, unless the COVID-19 vaccines are added to VICP. VICP provides compensation for injuries and deaths associated with vaccines that are listed on the Vaccine Injury Table and subject to an excise tax.

Congress created the VICP via the National Childhood Vaccine Injury Act of 1986 (NCVIA) amid concerns that lawsuits against vaccine manufacturers and health care providers alleging vaccine injuries could deter pharmaceutical innovation, lead to vaccine shortages, and lower immunization rates. Under a typical state tort law framework, an injured person must generally prove that a vaccine caused the injury and that either the vaccine manufacturer is at fault (e.g., negligent, failed to warn adequately) or, under products liability doctrines, that the vaccine was defective. If the person cannot prove one of these elements—for example, if the manufacturer adequately warned of side effects or it is unclear whether the vaccine caused the injury—the claimant receives no compensation. If the vaccine manufacturer is found liable, however, it may be responsible for compensatory damages and potentially punitive damages as determined by a judge or jury. Regardless of the outcome, both sides generally would be responsible for their own litigation costs.

The NCVIA created a no-fault alternative compensation program for deaths and injuries caused by certain vaccines that are recommended by the CDC for routine administration in children or pregnant women. The Program shields vaccine manufacturers from most tort liability for vaccine-related injuries and deaths, while providing compensation to those injured from a trust fund funded by excise taxes paid by the vaccine manufacturers. By limiting liability exposure for vaccine manufacturers, expanding the availability of compensation for injured parties, and lowering the burden of proof, the Program reduces uncertainty for both injured persons and vaccine manufacturers. From implementation of the Program in 1988 through February 1, 2023, more than 25,860 petitions for compensation have been filed, of which 21,907 have been adjudicated, with 9,565 determined to merit compensation. The Program has paid out more than...
$4.9 billion in compensation since its inception, and the Trust fund has a current balance of more than $4.3 billion.\(^{67}\)

**Covered Vaccines and Injuries**

To receive compensation through VICP, the injured person must have received a vaccine that is (1) recommended by the CDC for routine administration to children or pregnant women, (2) listed by the Secretary on the Vaccine Injury Table, and (3) subject to an excise tax that funds the Vaccine Injury Compensation Trust Fund from which compensation is paid.\(^{68}\) The types of vaccines subject to the excise tax are specified in statute and therefore can be amended only by an act of Congress.\(^{69}\)

To be entitled to VICP compensation, an injured party must first show receipt of a “covered vaccine.”\(^{70}\) Not every FDA-approved vaccine is covered by VICP. The NCVIA included an initial Vaccine Injury Table listing vaccines covered by the Program.\(^{71}\) Under the Act, the Secretary may promulgate regulations to amend the Vaccine Injury Table to include additional vaccines recommended by the CDC for routine administration to children or pregnant women within two years of such a recommendation.\(^{72}\)

In addition to having received a covered vaccine, the injured party must show either that (1) they experienced an injury listed for the vaccine in the Vaccine Injury Table and the first symptom of the onset or significant aggravation of the injury occurred within the timeframe specified in the Table, or (2) the vaccine more likely than not caused the injury.\(^{73}\) The Vaccine Injury Table allows injured persons to avoid having to prove a vaccine caused their injuries by allowing them instead to show they received an injury that has been temporally associated with receipt of a covered vaccine.\(^{74}\) Individuals who allege vaccine-related injuries not included in the Table, or who allege a Table injury but experience symptom onset outside of the specified timetable, may still file a petition. To be entitled to VICP compensation, such individuals are required to prove, by a preponderance of the evidence, that the vaccine received was the “but-for” cause of the injury.\(^{75}\)

**Procedure for Obtaining Compensation**

To receive VICP compensation, the injured person (or the estate in the case of a death) files a petition with the U.S. Court of Federal Claims (Claims Court).\(^{76}\) The petition must generally contain an affidavit and supporting documentation, including relevant medical records, showing the person:

---


\(^{69}\) 26 U.S.C. § 4132.

\(^{70}\) 42 U.S.C. §§ 300aa-11(c), 300aa-33(5).

\(^{71}\) *Id.* § 300aa-14(a).

\(^{72}\) *Id.* § 300aa-14(c).

\(^{73}\) *Id.* § 300aa-11(c). For more information about OSM proceedings, the adjudication of vaccine petitions, and proving causation, see CRS In Focus IF12213, *The National Vaccine Injury Compensation Program and the Office of Special Masters*, by Hannah-Alise Rogers (last updated Sept. 14, 2022).

\(^{74}\) 42 U.S.C. §§ 300a-11, 300aa-14.

\(^{75}\) *Id.* § 300a-11(c)(1)(C)(ii).

\(^{76}\) *Id.* § 300aa-11.
• received a vaccine listed in the Vaccine Injury Table;
• sustained or experienced a significant aggravation of an illness, disability, injury, or condition either:
  • set forth in the Vaccine Injury Table for the particular vaccine, and the first symptom or manifestation occurred within the required time period; or
  • caused by the vaccine;
• suffered residual effects or complications that lasted for more than six months or required inpatient hospitalization and surgery, or died; and
• has not collected another award or settlement for the injury or death.\textsuperscript{77}

Petitions for vaccine-related injuries must generally be filed within three years of the first symptom of the injury or significant aggravation.\textsuperscript{78} Petitions for vaccine-related deaths must be filed within two years of the death and within four years of the first symptom or significant aggravation of the injury from which the death resulted.\textsuperscript{79} If the Vaccine Injury Table is amended such that a person qualifies for compensation who previously did not, that person has two years from when the Table is revised to seek compensation for injuries or deaths that occurred up to eight years before the Table was revised.\textsuperscript{80}

When a person files a petition with the Claims Court, the clerk of the court forwards the petition to the Office of Special Masters (OSM), and the chief special master assigns the petition to one of the eight special masters.\textsuperscript{81} The court’s guidelines for attorneys practicing in the VICP, referred to as the Vaccine Rules, require the Secretary to review the petition within 30 days of its filing to determine whether the record is complete and to determine the government’s position on the appropriateness of compensation.\textsuperscript{82} Instead of filing a formal answer to the petition, as would be required in traditional court proceedings, the Secretary is required to file a report within 90 days of the petition’s filing outlining any legal and/or factual issues with petitioner’s claim and any medical conclusions reached by the Secretary’s experts.\textsuperscript{83} The 90-day period is often extended for a variety of reasons, for example because more time is needed to file additional medical records, the special master ordered the petitioner to file an expert report, or the parties wished to discuss settlement.\textsuperscript{84}

Approximately 60% of compensated petitions are the result of a settlement agreement.\textsuperscript{85} If the parties cannot resolve the case via settlement, the special master may hold an evidentiary hearing

\textsuperscript{77} Id. § 300aa-11(c).
\textsuperscript{78} Id. § 300aa-16(a).
\textsuperscript{79} Id.
\textsuperscript{80} Id. § 300aa-16(b).
\textsuperscript{81} Id. §§ 300aa-12(c)(1), 300aa-12(d); see also Vaccine Claims/Office of Special Masters, U.S. COURT OF FEDERAL CLAIMS, https://www.uscfc.uscourts.gov/vaccine-programoffice-special-masters (last visited Nov. 24, 2021).
\textsuperscript{83} Id.
\textsuperscript{84} Id.
on the petition or issue a ruling based on the administrative record.\textsuperscript{86} In either case, the assigned special master issues a decision regarding whether the petitioner is entitled to compensation under VICP and, if so, how much.\textsuperscript{87} Vaccine hearings resemble civil trials in that they allow for the presentation of evidence, including testimony from expert witnesses, but VICP proceedings offer more flexible, informal procedures to allow for expeditious resolution.\textsuperscript{88} The special master has 240 days from the date a petition is filed to issue an entitlement decision that includes factual findings and legal conclusions, though the parties may suspend the proceedings by motion for up to 150 days if necessary.\textsuperscript{89}

The petitioner has 30 days after the special master issues an entitlement decision to appeal the decision to the Claims Court.\textsuperscript{90} The court then has 120 days to uphold the decision, issue its own decision, or remand to the special master for further proceedings.\textsuperscript{91} If the parties do not appeal the special master’s decision within 30 days, or when the Claims Court issues a decision after review, judgment is entered and the petitioner has 60 days to appeal the judgment to the U.S. Court of Appeals for the Federal Circuit (Federal Circuit).\textsuperscript{92} If the parties choose not to appeal the decision, the judgment becomes final.\textsuperscript{93}

After a final judgment, the petitioner has 90 days to accept or reject the judgment.\textsuperscript{94} If the judgment awards compensation and the petitioner chooses to accept the judgment, the petitioner is entitled to an award of compensation but may not file a civil action for damages related to the injury or death. If the judgment awards compensation but the petitioner rejects the judgment, the petitioner is not entitled to any compensation from the VICP but may file a civil action for damages against the manufacturer.\textsuperscript{95} Petitioners who do not act to accept or reject the judgment within 90 days are deemed to have accepted the judgment and are also barred from filing civil claims.\textsuperscript{96} A petitioner may also withdraw the petition and file a civil action if the special master fails to act within 240 days or the Claims Court fails to enter the judgment within 420 days, both time frames excluding any suspended time.\textsuperscript{97} (Petitioners may opt not to withdraw their petitions if they do not want to risk proceeding in civil court.\textsuperscript{98})

In addition to limiting the availability of civil actions against manufacturers to parties who have gone through the VICP’s process, the NCVIA imposes certain limitations on vaccine

---


\textsuperscript{87} 42 U.S.C. § 300aa-12.


\textsuperscript{89} 42 U.S.C. § 300aa-12(d)(3). In practice, it takes approximately two to three years for the OSM to adjudicate petitions, according to HRSA data. See infra note 87, at 7.

\textsuperscript{90} 42 U.S.C. § 300aa-12(e)(1).

\textsuperscript{91} Id. § 300aa-12(e)(2).

\textsuperscript{92} Id. § 300aa-12(e)--(f).

\textsuperscript{93} Id. § 300aa-12(e)(3).

\textsuperscript{94} Id. § 300aa-21(a)(1).

\textsuperscript{95} Id. § 300aa-21(a).

\textsuperscript{96} Id. § 300aa-11(a)(2)(A).

\textsuperscript{97} Id. § 300aa-21(b).

\textsuperscript{98} Id.
manufacturers’ liability in civil proceedings. For example, vaccine manufacturers cannot be held liable for injuries or deaths due to unavoidable side effects from properly prepared vaccines accompanied by proper directions and warnings. Any action that proceeds against a vaccine manufacturer is tried in three stages: (1) liability, (2) general damages, and (3) punitive damages. Trifurcating the trial in this manner limits the evidence presented to the judge or jury in the first and second stages to the evidence relevant to each stage of the trial.

Available Compensation

An award for compensation includes:

- actual and reasonably projected unreimbursable expenses resulting from the vaccine-related injury, including the cost of diagnosis, medical care, rehabilitation, counseling, vocational training, and custodial care, among others;
- actual and anticipated loss of earnings;
- actual and projected pain and suffering and emotional distress, capped at $250,000;
- the amount of $250,000, in the case of a vaccine-related death; and
- reasonable attorneys’ fees and other costs associated with proceeding on the petition.

The NCVIA authorized appropriations to compensate individuals injured by vaccines administered before October 1, 1988. Compensation for injuries related to vaccines administered after October 1, 1988, is paid out of the Vaccine Injury Compensation Trust Fund (Trust Fund). Vaccine manufacturers pay into the Trust Fund through excise taxes imposed on covered vaccines. The Trust Fund may only be used to pay for vaccine-related injuries from vaccines subject to the excise tax at the time of payment, and for certain government administrative expenses incurred when administering the Program. Consequently, only vaccines subject to the excise tax are included in VICP.

Possible Transition of COVID-19 Vaccines from Coverage Under CICP to VICP

While they remain covered by the PREP Act Declaration, CICP—not VICP—is the exclusive remedy for injuries associated with the administration of COVID-19 vaccines. As explained in

99 Id. § 300aa-22.
100 Id. § 300aa-22(b).
101 Id. § 300aa-23.
102 Id. § 300aa-15(a)–(e).
103 Id. § 9510(c).
104 Id. § 300aa-15(i)(2); 26 U.S.C. § 9510.
detail in a separate CRS product, the applicable time period for liability immunity under the PREP Act may depend on the type of countermeasure, the means of distribution, the covered person who administers the countermeasure, and other factors. As a result, when coverage under the PREP Act Declaration expires depends on the particular context.

For COVID-19 vaccines purchased or distributed by the federal government—which at present includes all COVID-19 vaccines administered in the United States—PREP Act coverage currently extends through October 1, 2024. CICP would therefore continue to apply to COVID-19 vaccine injuries during that period for federally-purchased vaccines. However, if COVID-19 vaccines eventually transition to distribution through the private market, PREP Act coverage may end sooner than October 1, 2024, for those vaccines. Under the current PREP Act Declaration, PREP Act coverage for COVID-19 countermeasures not related to a federal contract generally extends through (a) the final day an applicable Declaration of Emergency is in effect, or (b) October 1, 2024, whichever occurs first. The Biden Administration has stated its intention to terminate the federal public health emergency declared under Section 319 of the Public Health Service Act on May 11, 2023. In light of that decision—unless a state or local emergency declaration applies or HHS amends the Declaration—PREP Act coverage for some COVID-19 countermeasures may end prior to October 1, 2024.

When COVID-19 vaccines are no longer covered by the PREP Act, CICP will no longer be an available remedy for injuries caused by COVID-19 vaccines. At that point, unless the vaccines are included in VICP, persons injured by COVID-19 vaccine side effects could pursue remedies under state tort law.

After the expiration of PREP Act coverage, Congress could decide to add COVID-19 vaccines to the VICP. To accomplish this under existing law, (1) the CDC must recommend the vaccine for routine administration to children and/or pregnant women; (2) Congress must enact legislation to apply the excise tax to the vaccine; and (3) the Secretary of HHS must add the vaccine to the Vaccine Injury Table by publishing a notice of coverage. Should all three of these changes occur, the COVID-19 vaccine would be added to the VICP with coverage effective as of the date of the enacted tax.

---


111 See Hickey, supra note 108; Tenth PREP Act Declaration Amendment, supra note 108, at 988. If COVID-19 vaccines are eventually purchased and distributed through private channels, PREP coverage could potentially terminate earlier, depending on whether the public health emergency declarations for COVID-19 remain in effect.


113 See id.; Hickey, supra note 108.


115 See HHS Fact Sheet, supra note 112.

116 42 U.S.C. § 300aa-14(e)(2); 42 C.F.R. § 100.3(a)(XVII).

117 42 U.S.C. § 300aa-14(e)(2). Under 42 U.S.C. § 300aa-14(e)(2), when the CDC recommends a new vaccine for routine administration to children or pregnant women, the Secretary is required to amend the Vaccine Injury Table.
On October 20, 2022, the CDC’s Advisory Committee on Immunization Practices recommended adding COVID-19 vaccines (specifically, the Pfizer, Moderna, and Novavax vaccines) to the regular childhood and adult immunization schedules.\textsuperscript{118} Vaccines added to the regular CDC immunization schedules are considered recommended for routine use for the purposes of VICP.\textsuperscript{119} The CDC formally adopted the recommendation on February 10, 2023, when the recommendation was published in the Morbidity and Mortality Weekly Report.\textsuperscript{120} This recommendation triggers a statutory obligation for the Secretary to amend the Table to include the COVID-19 vaccine; the injuries, conditions, or deaths that are associated with the vaccines; and the time period in which onset of symptoms or significant aggravation of symptoms must occur.\textsuperscript{121} Under the HHS vaccine regulations, the Secretary adds a vaccine to the Table by issuing a notice of coverage, which generally states that the vaccine is covered by the VICP as of the date the excise tax applies to the vaccine.\textsuperscript{122} Any changes made to the Vaccine Injury Table to add COVID-19 vaccines do not become effective until and unless Congress enacts legislation to extend the excise tax to the COVID-19 vaccines.\textsuperscript{123}

**Considerations for Congress**

The inclusion of COVID-19 vaccines in CICP and their possible transition to VICP present several issues that Congress may consider.

Because of the widespread use of COVID-19 vaccines, HRSA is receiving a volume of claims under the CICP many times larger than it has received during past public health emergencies. To date, HRSA has reached decisions on less than 5% of the COVID-19-related claims it has


\textsuperscript{119} See, e.g. 62 FR 7685 (Feb. 20, 1997) (Final rule adding hepatitis B vaccine to the Table); 62 FR 52724 (Oct. 9, 1997) (the notice of compensation for hepatitis B); 63 FR 25777 (May 11, 1998) (The final rule adding a date certain for coverage for hepatitis B vaccine). See also 69 FR 69945 (Dec. 1, 2004), which is the notice of coverage adding Hepatitis A vaccine to the Table, where the CDC explains, “The two prerequisites for adding Hepatitis A vaccines to the VICP as covered vaccines as well as to the Table have been satisfied. First, the CDC published its recommendation that Hepatitis A vaccines be routinely administered to certain children in the October 1, 1999 issue of the Morbidity and Mortality Weekly Report (MMWR)...”

For more information on the ACIP and its recommendations, see CRS In Focus IF12317, The Advisory Committee on Immunization Practices (ACIP), by Kayya Sekar.

\textsuperscript{120} CDC, Morbidity and Mortality Weekly Report, Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger – United States, 2023, Feb. 10, 2023, available at https://www.cdc.gov/mmwr/volumes/72/ww/mm7206a1.htm?s_cid=mm7206a1_w#contribAff (last accessed Mar. 8, 2023).

\textsuperscript{121} 42 U.S.C. § 300aa-14(e)(2)–(3).

\textsuperscript{122} See id.; 42 CFR § 100.3(a).

\textsuperscript{123} See 42 U.S.C. § 300aa-14 note.
received. Congress may wish to consider whether HRSA needs additional authorities or resources to process these CICP claims expeditiously.

CICP is a more limited program than VICP in several ways. The available compensation is generally lower, and the standard of proof for non-Table injuries is higher. There are fewer opportunities for appeal and reconsideration in CICP as judicial review is not available. CICP claimants have lower rates of success on average as compared to VICP petitioners. Congress may wish to consider whether barriers to CICP compensation could be lowered, or—as some observers argue—the law could be changed so that COVID-19 vaccine injury claims could be brought under VICP.

CICP has also been criticized for lacking transparency and accountability, and having high administrative costs relative to the amounts it awards in compensation. To some degree, the high costs may be attributable to the relatively high standard of proof and lower success rates for CICP claims. Regardless, Congress may consider whether CICP is an efficient way to compensate these claims, and whether judicial review or greater transparency in HRSA’s decisionmaking process would improve the Program.

Congress could also choose to implement an entirely new program specifically addressing compensation for COVID-19 vaccine-related injuries or deaths. Alternatively, Congress could opt to leave COVID-19 vaccines out of VICP and allow the traditional tort system to address any vaccine-related injuries after CICP no longer applies.

Covering COVID-19 vaccines under VICP presents issues Congress may wish to consider as well. As discussed above, VICP awards are funded by an excise tax and the Program may only compensate injuries resulting from “taxable vaccines” subject to the excise tax. “Taxable vaccines” are defined in the tax code to include vaccines against particular diseases, which does not include COVID-19. Should Congress wish to include COVID-19 vaccines in VICP following the expiration of coverage under the PREP Act and CICP, it would need to amend the statute to subject COVID-19 vaccines to this excise tax. Alternatively, to facilitate the process of adding new vaccines to the Program, Congress could consider subjecting to the tax any vaccine recommended for routine administration by the CDC.

Congress could also decide to change altogether the process outlined above for adding new vaccines to VICP, outline a new program for compensation for COVID-19 vaccine injuries and deaths, or create a new program applicable only to pandemic vaccines.

127 See 26 U.S.C. §§ 4131, 9510(c).
128 Id. § 4132(a).
129 H.R. 3656, the Vaccine Access Improvement Act of 2021 (117th Cong.), introduced on June 1, 2021, proposed amendments to the Internal Revenue Code (26 U.S.C. § 4132(a)(1)) to automatically subject to the excise tax any vaccine the Secretary adds to the Vaccine Injury Table.
130 H.R. 5687, the Backing the Independent Decisions of Employees Against Nefarious Mandates Act of 2021, (117th Cong.), introduced on October 21, 2021, proposed to authorize a private right of action in federal district court for employees who suffer a vaccine-related injury or death as a result of receiving a COVID-19 vaccine that is mandated by their employer.
Should Congress add COVID-19 to the excise tax and COVID-19 vaccines become covered by VICP, processing COVID-19 vaccine claims under the VICP may present other issues, absent further congressional action. For example, the NCVIA caps the number of special masters who may adjudicate petitions at eight.\textsuperscript{131} Petitioners being able to file VICP petitions for injuries related to COVID-19 vaccines would likely result in a substantial increase to the OSM caseload, which has already grown in recent years. For example, in Fiscal Year (FY) 2021, vaccine petition filings increased by 72.6\% over FY2020, and there have been more than 1,000 petitions filed in the Program every year since FY2015.\textsuperscript{132} As of September 30, 2022, there are currently more than 3,800 pending vaccine petitions.\textsuperscript{133} Congress may wish to amend the NCVIA to increase both the number of special masters who may adjudicate petitions as well as the OSM budget, so as to accommodate additional court staff.\textsuperscript{134}

In light of the potential increased caseload if COVID-19 vaccines are added to VICP, Congress could also consider increasing the staffing and resources of both the Department of Justice, which litigates VICP petitions on behalf of the government, and HRSA, which provides medical experts and administrative support to review the petitions and medical records filed to determine the government’s position on petitioner’s entitlement to compensation.\textsuperscript{135} According to HRSA, a backlog of cases awaiting review began in FY2017, and it currently takes the agency approximately 12 months to conduct its initial review of each petition,\textsuperscript{136} delaying the processing of petitions and the OSM’s adjudications.

\textsuperscript{131} 42 U.S.C. § 300aa-12(c)(1).
\textsuperscript{134} H.R. 3655, the Vaccine Injury Compensation Modernization Act, (117\textsuperscript{th} Cong.), introduced on June 1, 2021, proposed to amend the Public Health Service Act to establish a minimum of 10 special masters. The bill also proposed to increase compensation for pain, suffering, and death, and would have lengthened the statute of limitations for filing vaccine petitions from 36 months to five years.
\textsuperscript{136} Id. at 445.
Appendix. Comparison of Vaccine-Injury Programs: CICP vs. VICP

<table>
<thead>
<tr>
<th>Countermeasures Injury Compensation Program (CICP)</th>
<th>Vaccine Injury Compensation Program (VICP)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scope of Coverage</strong></td>
<td>“Covered countermeasures” under the PREP Act, such as pandemic and epidemic products used to treat, mitigate, prevent, or cure COVID-19 (e.g., vaccines, PPE, treatments)</td>
</tr>
<tr>
<td></td>
<td>“Covered Vaccines” are those recommended by CDC for routine administration to children or pregnant women, subject to a federal excise tax, and added to the Vaccine Injury Table</td>
</tr>
<tr>
<td><strong>Covered Injuries</strong></td>
<td>Death, or serious physical injury that (1) warrants hospitalization or (2) leads to a significant loss of function or disability</td>
</tr>
<tr>
<td></td>
<td>Death or an illness, injury, or condition that lasted more than six months or required inpatient hospitalization and surgical intervention and was associated with one or more vaccines in the Vaccine Injury Table (unless the cause was an adulterant or contaminant that was intentionally added to the vaccine)</td>
</tr>
<tr>
<td><strong>Process for Obtaining Compensation</strong></td>
<td>Administrative Process: file request form and supporting documentation with CICP to prove eligibility and compensation amounts</td>
</tr>
<tr>
<td></td>
<td>Judicial Process (“vaccine court”): file a petition in the U.S. Court of Federal Claims</td>
</tr>
<tr>
<td><strong>Available Benefits</strong></td>
<td>Reasonable medical expenses, lost employment income, and death benefits</td>
</tr>
<tr>
<td></td>
<td>Non-reimbursed expenses related to the injury for the diagnosis, medical care, and various rehabilitation and recovery services; lost employment income; pain, suffering, and emotional distress damages; death benefits; attorney’s fees</td>
</tr>
<tr>
<td><strong>Unavailable Benefits</strong></td>
<td>Attorneys’ fees, pain-and-suffering damages, punitive damages</td>
</tr>
<tr>
<td></td>
<td>Punitive or exemplary damages</td>
</tr>
<tr>
<td><strong>Benefit Caps</strong></td>
<td>$50,000/year for lost employment income; lifetime cap for lost income (except for permanent disability); and standard death benefit of $389,825.45 for FY2022</td>
</tr>
<tr>
<td></td>
<td>$250,000 for death; $250,000 for pain and suffering and emotional distress</td>
</tr>
<tr>
<td><strong>Filing Deadlines</strong></td>
<td>Within one year of administration of covered countermeasure (or within one year of the issuance of an amended Countermeasure Injury Table)</td>
</tr>
<tr>
<td></td>
<td>For injuries, within three years of the onset of the first symptom; for deaths, within two years of the death and four years of the onset of the first symptom</td>
</tr>
<tr>
<td><strong>Standard of Proof</strong></td>
<td>Must show the injury (1) meets the requirements on a Countermeasure Injury Table; or (2) was a direct result of the administration or use of a covered countermeasure</td>
</tr>
<tr>
<td></td>
<td>Must show the injured person (1) received a vaccine on the Vaccine Injury Table; (2) sustained or significantly aggravated an illness, disability, injury, or condition, or died; (3) the illness, disability, injury, condition, or death is either listed in the Vaccine Injury Table in association with the vaccine and occurred within a set time period as specified in the Table or was caused by the vaccine; (4) suffered the effects for more than six months or required inpatient hospitalization and surgery or died; and (5) has not previously collected an award for the injury or death</td>
</tr>
</tbody>
</table>
## Compensation Programs for COVID-19 Vaccine Injuries

<table>
<thead>
<tr>
<th><strong>Countermeasures Injury Compensation Program (CICP)</strong></th>
<th><strong>Vaccine Injury Compensation Program (VICP)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Initial Decisionmaker</strong></td>
<td>CICP (as delegate of the Secretary of HHS)</td>
</tr>
<tr>
<td><strong>Appeals &amp; Judicial Review</strong></td>
<td>Claimant may seek reconsideration of CICP decision to a qualified independent panel within 60 days; no further judicial or administrative review</td>
</tr>
<tr>
<td><strong>Funding Source</strong></td>
<td>Emergency appropriations to Covered Countermeasure Process Fund</td>
</tr>
<tr>
<td><strong>Number of Claims Processed</strong></td>
<td>Non-COVID-19 claims (2010–2023): 513 claims, of which 40 were determined eligible and 30 compensated (6%)</td>
</tr>
<tr>
<td></td>
<td>COVID-19 countermeasure claims (as of March 1, 2023): 11,252 claims, of which 8,067 (72%) allege injuries from COVID-19 vaccines; of the 630 claims reviewed for CICP eligibility, 21 (3.3%) have been held eligible for compensation; most claims (94%) remain in or pending review</td>
</tr>
<tr>
<td><strong>Process for Adding New Vaccines</strong></td>
<td>Scope of “covered countermeasures” is determined by Secretary of HHS’s PREP Act declarations (within statutory limits)</td>
</tr>
</tbody>
</table>

**Source:** 42 U.S.C. §§ 300aa-10–300aa-34; 42 U.S.C. § 247d-6d to -6e; 42 C.F.R. pt. 110; HRSA; CRS.

### Author Information

- **Kevin J. Hickey**
  Legislative Attorney

- **Erin H. Ward**
  Legislative Attorney

- **Hannah-Alise Rogers**
  Legislative Attorney
Disclaimer

This document was prepared by the Congressional Research Service (CRS). CRS serves as nonpartisan shared staff to congressional committees and Members of Congress. It operates solely at the behest of and under the direction of Congress. Information in a CRS Report should not be relied upon for purposes other than public understanding of information that has been provided by CRS to Members of Congress in connection with CRS’s institutional role. CRS Reports, as a work of the United States Government, are not subject to copyright protection in the United States. Any CRS Report may be reproduced and distributed in its entirety without permission from CRS. However, as a CRS Report may include copyrighted images or material from a third party, you may need to obtain the permission of the copyright holder if you wish to copy or otherwise use copyrighted material.